Lumicell, Inc.
PrivateLast Round
Series D
Extension
May 6, 2025
Est. Valuation
$250M
Total Funding Raised
$403.22M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Lumicell, Inc. operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series D Extension round in May 2025.
Lumicell, Inc. is a medical technology company that develops fluorescence-guided surgical imaging technologies to enable real-time detection and removal of residual cancerous tissue during surgery.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical Imaging, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lumicell, Inc. Comparables
Compare Lumicell, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dilon Technologies Inc. | 84% | |
| KUBTEC Medical Imaging | 80% | |
| Clarix Imaging | 79% |
For institutional investors. Book with your work email.
Lumicell, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | May 6, 2025 | ||||
| Series D | Jul 24, 2024 | ||||
| Series C | Mar 8, 2024 | ||||
| Series D | Jul 26, 2023 | ||||
| Series D | May 25, 2021 | ||||
Debt | Apr 15, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Lumicell, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Furneaux Capital | Series D |
| Quantum Valley Investments | Series D |
| Kodiak Venture Partners | Series D, Series C, Series D Extension |
| BlueIO | Series D, Series D Extension, Series C |
| Massachusetts Life Sciences Center | Debt |
| Rivas Capital | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 59% MoM.
- Apr 1, 2026
Fluorescence-guided surgery platform is now a commercially approved Class III medical device.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- promotesOct 19, 2026
Lumicell promotes Marnie Curbow from Vice President of Sales to Chief Commercial Officer, where she assumes responsibility for sales, marketing, reimbursement, and clinical applications, in Massachusetts on May 28th '26.
- expands_offices_inSep 15, 2026
Lumicell continues its commercial expansion in the United States breast lumpectomy market, including LumiSystem implementation at the nation’s leading cancer center, on Sep 15th '26.
For institutional investors. Book with your work email.
Lumicell, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Lumicell, Inc.'s valuation, stock price, and market status.
Is Lumicell, Inc. a public or private company?
Lumicell, Inc. is a private company.
What is the current stock price of Lumicell, Inc.?
Lumicell, Inc. is a private company, so its shares have no public market price. Caplight tracks Lumicell, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lumicell, Inc. worth (valuation)?
Lumicell, Inc.'s valuation is estimated at $250.0M based on funding round data.
Can I buy Lumicell, Inc. stock?
Lumicell, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lumicell, Inc.'s last funding round?
Lumicell, Inc.'s most recent funding round was Series D Extension on May 6, 2025.
Who are the main investors in Lumicell, Inc.?
Key investors in Lumicell, Inc. include Novo Holdings, Launch Capital, Glenview Capital Management.
Will Lumicell, Inc. IPO soon?
No public IPO plans have been announced for Lumicell, Inc..
How can I track Lumicell, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Lumicell, Inc.'s shares on secondary markets.